TENAYA and LUCERNE
Most Cited Paper
in Retinal Diseases and Treatments
18 Months Post-Publication
Class of 2026
“TENAYA and LUCERNE”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/
Topics
Faricimab · Faricimab · Angiopoietin-2 inhibition · Anti-VEGF therapy · Neovascular age-related macular degeneration · Aflibercept · Intravitreal injection · Treat-and-extend regimen · Every-16-week dosing · Q12W dosing · Q8W dosing · Best-corrected visual acuity (BCVA) · Noninferiority trial design · Treatment-naïve · Extended dosing interval · ocular adverse events · TENAYA trial · LUCERNE trial · disease activity-based dosing · Durability of treatment effect
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459